摘要
1992年7月至1993年2月,用NAVELBINE治疗35例Ⅲ—Ⅳ期的非小细胞肺癌患者,所有病例均经病理组织学证实,包括鳞癌12例,腺癌18例、肺泡癌3例、腺样囊腺瘤和大细胞癌各1例。实际可评价的病人34例,其中Navelbine单药治疗16例(25mg/m^2/周×4),5例PR,有效率为31.3％。联合治疗(Navelbine+CDDP)18例,CR1例(5.6％)PR8例(44.4％),总有效率为50％。主要毒性为骨髓抑制,白细胞减少Ⅲ—Ⅳ级发生率为32.4％,其中一例高龄者白细胞严重减少,合并败血症而死亡。该研究提示,Navelbine对非小细胞肺癌的治疗价值是肯定的,主要剂量限制毒性为骨髓抑制,应在肿瘤学专家的指导下使用。
I 35 Cases of advanced, stage III-IV NSCLC cases, previously untreated, were treated with NAVELBINE(NVB). All cases were histological approved, Epidermoid 12 cases, Adenocarcinoma 18 cases, aveolar cell carcinoma 3 cases and Cystadenocarcinoma 1 case, Large Cell care 1 case. 16 cases were treated with single drug weekly NAVELBI-NE 25mg/m 2 for at least 4 weeks, 5 cases (31.3%) achiveved PR. 18 cases were treated with weekly NAVELBINE for 3 weeks and DDP 80mg/m 2 single inj every 4 weeks, CR 1 case and PR 8 cases, overall response rate 50% . Myelosuppresskm was the main dose-limiting toxicity, Grade III-IV leucopenia occured in 32.4%, 1 elderly case developed severe leucopenia and died of sepsis. This study showed that NAVELBINE is effective in advanced NSCLC and should be used under dose supervision of oncologist.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1993年第3期217-219,226,共4页
Chinese Journal of Cancer
